Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Non Operating Income (2016 - 2026)

Oramed Pharmaceuticals filings provide 11 years of Other Non Operating Income readings, the most recent being -$39.2 million for Q4 2025.

  • Quarterly Other Non Operating Income fell 28917.04% to -$39.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.6 million through Dec 2025, down 107.92% year-over-year, with the annual reading at -$606000.0 for FY2025, 2144.44% down from the prior year.
  • Other Non Operating Income hit -$39.2 million in Q4 2025 for Oramed Pharmaceuticals, down from $32.3 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $32.3 million in Q3 2025 and bottomed at -$39.2 million in Q4 2025.